-
January 29, 2019
6:30 pm - 11:00 pm
-
Dr. Afshan Zahedi BASc, MD, FRCPC
Associate Professor of Medicine
Fellowship Program Director, Division of Endocrinology, University of Toronto
Medical Director, Thyroid program, Women’s College Hospital
Objectives:
- Review the 2018 Diabetes Canada recommendations for management of GDM.
- Outline management strategies for pre-gestational diabetes
- Discuss the 2017 ATA guidelines for management for thyroid disease in pregnancy
- Highlight changes in management of subclinical hypothyroidism and hyperthyroidism in pregnancy
Sponsored by:
Venue
The University Club of Toronto
Tel: 416-597-1336
www: http://www.universitycluboftoronto.com/
Heritage, Tradition and the Future.
Located on Toronto’s prestigious University Avenue, in the heart of the City, the University Club of Toronto is housed in a cherished heritage building that is a retreat for members to dine, socialize, pursue intellectual or artistic enlightenment via the Club’s many events or perhaps visit our boutique fitness centre.
But the Club is more than just its location or bricks and mortar (however awe inspiring those might be!) it is place where connections are forged; relationships are built and friendships made. The Club is warm and welcoming; collegial and engaging. Since 1906 it has been a community of people of diverse backgrounds and interests respectful of traditions yet fully immersed in the contemporary world seeking comfort, familiarity, friendship amongst a body of members with shared interests.
Get driving directions to this event
Event Sponsor Information
Ferring Pharmaceuticals is a research-driven, biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopaedics.
The company’s research activities and products are connected by a common focus of providing tailored treatments that work on the body’s own terms, enabling doctors to combat numerous diseases and medical conditions.
Ferring has its own manufacturing facilities in several European countries, in South America, Israel, India and China. It is also currently building new facilities in the USA. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by the corporate headquarters in Saint-Prex, Switzerland, operate from nearly 60 countries and employ over 6,000 people throughout the world, while treatments are available in 110 countries. This expansion has allowed Ferring to maintain a double-digit annual growth rate over the last two decades.
https://www.ferring.ca/en/home/